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The methodologist’s point of view
Gianni Virgili, Andrea A. Conti, Lorenzo Moja
As the Cochrane Corner hosts analytical comments on
Cochrane systematic reviews (SRs), it is important that
readers are comfortable in understanding the methodology
related to SR science. In the first article in this series, we
presented an approach to understand all basic information
reported in a meta-analysis graph [1]. In this issue, we
cover concepts and tips related to heterogeneity, and
whether to combine the results of the studies is appropriate.
The decision to meta-analyse or not to meta-analyse studies
may appear imponderable to many clinicians. How do
authors decide whether patients, interventions and out-
comes considered in individual studies are sufficiently
similar to be pooled in meta-analyses?
Sources of diversity of results across studies in an SR:
clinical, methodological and statistical heterogeneity
Systematic reviews synthesise the results of several com-
parative studies that investigate the same research ques-
tions. Such studies often yield diverse estimates of
treatment effect, and reviewers need to evaluate whether
the variation in the true effects underlying the studies is
within the boundaries of chance. As an example, Moncrieff
et al. [2] find in randomised controlled trials (RCTs) that
antidepressants compared with active placebo are mainly
beneficial, although these trials present highly variable
treatment effects (Fig. 1a). Is the overall estimate diamond
at the bottom of the meta-analysis graph a good descriptor
of all study results? There may be reason to be cautiously
sceptical about the capacity of the meta-analysis to com-
pact such heterogeneity in a precise estimate. The sceptic
should ask first where all this heterogeneity comes from.
Reasons of heterogeneity are usually classified into
clinical (participants, interventions and outcomes) and
methodological (design and conduct) diversities. For
example, interventions can differ because of drug dosage or
treatment duration, or, if they are about quality improve-
ment, because they include a number of components that
may be only partly similar. Conduct can differ because
some researchers have kept study participants and those
involved with their management unaware of the assigned
treatment (sometimes called blinding or masking), and
others have not. Blinding is, particularly, important
when the response criteria are subjective, such as an
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improvement in depression [3]. Moncrieff et al. hypothe-
sise that heterogeneity could arise from the use of different
scales to measure the primary outcome: change of mood,
inclusion of outpatients versus inpatients, or a variable
length of follow-up [2].
The relevance of heterogeneity will vary according to
the circumstances. Some reviews are purposely broad, and
the authors may need to decide on what is similar and what
is not, facing the trade-off between the opportunity to pool
‘oversize’ accumulated evidence and the risk of pooling
apples and oranges, making the meta-analysis less inter-
pretable. Other meta-analyses include studies that deal with
similar clinical and methodological aspects, and hetero-
geneity could be unexpected.
Once scepticism regarding clinical and methodological
diversities has been considered, there is a third source to
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Fig. 1 a Fixed-effect meta-analysis of studies comparing antidepres-
sants with active placebo for depression as conducted by Moncrief
et al. [2]. b The correspondent random-effects meta-analysis. The
weights of extreme observations such as Daneman (1991) are reduced
using random effects and the resulting 95% CI of the pooled estimates
are much wider because of unexplained high heterogeneity
(I2 = 78%, P \ 0.0001) of treatment effect across studies is
accounted
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explore: statistical heterogeneity that can be interpreted as
clinical and methodological heterogeneity of unknown
source. Statistical heterogeneity manifests itself in the
observed intervention effects being more different from
each other than one would be expect due to chance (ran-
dom error) alone. A user-friendly way of describing sta-
tistical heterogeneity is the following: does a meta-analysis
of similar RCTs suggest a unique true estimate of treatment
effect underlying the studies? Or rather, do individual
studies’ estimates suggest that treatment worked differently
in different studies, and we can expect a range of several
efficacies?
When there is large heterogeneity of treatment effects
across studies, we infer that there is no unique underlying
truth to measure, but rather that we are sampling from a
range of treatment effects even if a single drug has been
used as an intervention. When researchers are unable to
explain why this variability occurred, we refer to
unknown factors that have modified treatment efficacy
across studies.
Methods for measuring statistical heterogeneity
The Cochran’s Q and the I2 statistics are related measures
of statistical heterogeneity of treatment effect across
studies [4, 5]. All Cochrane meta-analyses report these
statistics at the bottom of the meta-analysis graphs.
The Q statistic leads to a P value. The power of this test
is often modest, given the small number of studies in
typical meta-analyses, and a P value of 0.10 is used as a
threshold for significance [4]. The Cochrane Handbook for
SRs of interventions recommends the use of the I2 statistic
to measure statistical heterogeneity [5]. The I2 statistic
leads to a percentage value. In effect, the I2 describes the
percentage of the variability in effect estimates that is due
to heterogeneity rather than chance (sampling error) [4, 5]
and is in fact an estimate of the between-study variance to
the total variance (between plus within study). Let the
negative values of I2 be equal to zero so that I2 lies between
0 and 100%. A value of 0% indicates no observed heter-
ogeneity, and larger values show increasing heterogeneity
[4].
At this point, clinicians have to ask themselves whether
a meta-analysis is reasonable. The Cochrane Handbook
gives the following guidance on this decision based on I2
values to classify the inconsistency of the effect measures
(often relative risks, odds ratios or mean differences) across
studies [5]:
• 0–40%: might not be important
• 30–60%: may represent moderate heterogeneity
• 50–90%: may represent substantial heterogeneity
• 75–100%: considerable heterogeneity.
The importance of the observed I2 values also depends
on:
• The magnitude and direction of the effects: if I2 is
[50%, but all studies are in the direction of benefit and
a random-effect meta-analysis (see following para-
graph) yields highly statistically significant benefit,
then we are uncertain about the amount of benefit, but
not about its existence. Then, it is safe to conclude that
the treatment is beneficial.
• The strength of evidence from heterogeneity, e.g. the P
value from the v2 test for heterogeneity or a confidence
interval for the I2: as an example, the I2 statistics of
78% (95% confidence interval from 59 to 88%,
P = 0.000) obtained from the meta-analysis by
Moncrieff et al. [2], provides large evidence of hetero-
geneity. In this case, three possible solutions are: (1) to
avoid a meta-analysis, (2) to explore heterogeneity (i.e.
subgroup analysis), or (3) to carry out a random-effect
meta-analysis.
Random effects estimate of treatment effect
in a meta-analysis
If no clinical, methodological and statistical heterogeneity
are found, the studies can be assumed to measure an
underlying unique treatment effect. Therefore, we can
simply pool individual studies’ mean differences (or other
effect measures) as a weighted average of the mean dif-
ference of each study. Commonly, weights are the inverse
of the mean difference variance; the more the study is
precise compared with the others in the meta-analysis, the
more will be the weight given. This is also called a fixed-
effect meta-analysis (Fig. 1a).
When heterogeneity is recognised, we should be able to
estimate the variability of the presumed true value of
treatment efficacy across studies (between-study variabil-
ity), taking into account the uncertainty due to the fact that
each study is imprecise (within-study variability). It seems
straightforward that we place more uncertainty on our
mean difference estimate when heterogeneity is found, and
this should be done proportionally to how much of statis-
tical heterogeneity exists. A statistic called s (tau) is the
technical estimate of this extra variability of unknown
source, and is used to inflate confidence intervals of mean
differences in a random-effect meta-analysis (Fig. 1b).
This will lead to a more conservative estimate of the
amount of benefit, if a benefit is found, as compared to a
fixed-effect meta-analysis.
The antidepressant review example, Fig. 1, presents the
differences between fixed- and random-effect meta-analy-
ses when large heterogeneity exists [2]. From one approach
to the other, there is a change in study weights (last
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columns in the meta-analysis graph). The overall estimate
of diamond at the bottom of the random-effect meta-
analysis graph is inflated incorporating more heterogeneity.
Clinicians should consider that incorporating heterogeneity
does not eliminate heterogeneity. Some clinicians would
still consider insufficient to use a random-effect approach
for the different studies considered by Moncrieff et al. and
reject the proposed meta-analysis as overly broad.
Heterogeneity could be also explored using other
approaches, such as subgroup analyses or the more
sophisticated meta-regression, to try to explain diversity of
effects, grouping studies by drug type or dose, by patients’
age, by high versus low risk of bias according to the study
methodological quality, etc. Subgroup analyses and inter-
action tests will be discussed in a following Cochrane
Corner.
Statistical heterogeneity when only one trial is found
Evidence from a single study is believed to be weaker as
compared to that from a meta-analysis. When the results of
a single trial show that a treatment is superior to control,
the limits of the 95% confidence interval of the effect
estimate should be far from equivalence to be resistant to
assumptions regarding heterogeneity when multiple trials
were conducted and included in a meta-analysis. When
only one trial is found for a given comparison in an SR, we
will be unable to estimate the potential heterogeneity of
treatment effects. Borm et al. [6] recently suggest that the
confidence intervals of the effect measure from a single
study should be inflated to take into account potential
heterogeneity amongst multiple trials. Assuming hetero-
geneity I2 of 25, 50 or 75% in a meta-analysis including a
trial, the 95% confidence interval around the point estimate
of this trial would be more consistent with the meta-anal-
ysis results if they are inflated by 115, 141 or 200%,
respectively. Transferring this information to the P value
scale, a P value of 0.001 from a test of statistical signifi-
cance would become a P value of 0.02 after inflating
confidence intervals by 141%, meaning that considerably
more uncertainty regarding the amount of treatment benefit
would be found assuming moderate heterogeneity of
treatment effect in future research.
Conclusion
Heterogeneity of results from RCTs and other studies
informs us that a single trial is just a sample drawn from a
pool of potentially diverse pieces of research conducted in
different settings. As a matter of fact, a single study is not
testing the theoretical efficacy of an intervention, as if
patients and doctors were acting in a laboratory, but it
rather tries to measure the effect of an intervention that
may remain a component of a complex and variable clin-
ical pathway, despite the adoption of study protocols.
Understanding the concept of heterogeneity is central in
clinical research, and possible heterogeneity sources should
be targeted and hopefully, resolved on the question on
hand.
A clinician’s point of view
Gian Franco Gensini, Roberto Gusinu, Andrea A. Conti
Meta-analyses are powerful research tools used to sum-
marise in a quantitative way the results of clinical trials [7].
As for every powerful instrument, their correct use is
fundamental, and Gianni Virgili et al. has clearly explained
in the first part of this paper the potentialities and bound-
aries of application of meta-analyses.
Clinicians are, nowadays, more and more familiar with
the publication of meta-analyses in prestigious biomedical
journals, yet the full elucidation of heterogeneity is
appropriate, since heterogeneity has different dimensions,
including the clinical, the methodological and the statistical
ones, which may relevantly influence the interpretation of
scientific literature [8]. Clinical heterogeneity will be
briefly discussed here with specific regard to the clinician’s
point of view.
Even if meta-analyses are today conducted not only on
controlled clinical studies, but also on case–control and
cohort studies, the number of meta-analyses selectively
containing clinical trials is on the increase. The PICO
model is a precious guide in this area [9]. The acronym
PICO stands for Patients, Interventions, Comparators and
Outcomes, and indicates the basic variables that have to be
taken into account as a potential generators of clinical
heterogeneity.
The variable ‘‘Patients’’ refers to the demographic and
clinical characteristics of the people enrolled in controlled
trials; the sample included in the clinical study should
always be carefully analysed with respect to age and gen-
der distribution and to pathological features (stage, length
and seriousness of the single diseases or of the multiple
pathologies, i.e. comorbidity, investigated). The variable
‘‘Interventions’’ regards the type, pattern and modality of
the health measures implemented, which can include far
different interventions, such as, for example, pharmaco-
logical, lifestyle and invasive measures. The variable
‘‘Comparators’’ concerns not only the kind of comparator
used in controlled trials, but also the way comparisons are
performed. Historically, early clinical trials compared one
intervention with no intervention or with placebo [10].
Subsequently, established individual health interventions
have been head-to-head compared with newly proposed
426 Intern Emerg Med (2009) 4:423–427
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measures. More recently, the predominant model of clini-
cal trials available effects a comparison, at least in the
therapeutic pharmacological area, between a new drug on
top of the best therapeutic armamentarium available and
the same optimal therapeutic pattern without the new drug.
The variable ‘‘Outcomes’’ deals with the evaluation
parameters examined in controlled studies. They too are a
potential source of heterogeneity, according to whether
they are subjective or objective, on the basis of the time
period in which they are collected and analysed and with
regard to their being simple or composite end points. At
present, there is an interesting and ample ongoing inter-
national debate on the appropriateness and drawbacks of
the use of composite or combined end points.
Although not included in the acronym PICO, the
importance of clinical and health-care settings in controlled
studies is fundamental, and not by chance does the evi-
dence-based model of synthesis of clinical trials explicitly
foresee it. The full consideration of the PICO model,
therefore, appears to be of paramount importance in
assessing controlled trials and identifying the possible
sources of heterogeneity in clinical research. Furthermore,
it constitutes a cornerstone of methodological evaluation
given that, even when problems regarding clinical diversity
are resolved, statistical heterogeneity may still be present
and observable.
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